![Problems and solutions in calculating quality-adjusted life years (QALYs) | Health and Quality of Life Outcomes | Full Text Problems and solutions in calculating quality-adjusted life years (QALYs) | Health and Quality of Life Outcomes | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1477-7525-1-80/MediaObjects/12955_2003_Article_80_Fig1_HTML.jpg)
Problems and solutions in calculating quality-adjusted life years (QALYs) | Health and Quality of Life Outcomes | Full Text
![The economic benefit of hip replacement: a 5-year follow-up of costs and outcomes in the Exeter Primary Outcomes Study | BMJ Open The economic benefit of hip replacement: a 5-year follow-up of costs and outcomes in the Exeter Primary Outcomes Study | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/2/3/e000752/F1.large.jpg)
The economic benefit of hip replacement: a 5-year follow-up of costs and outcomes in the Exeter Primary Outcomes Study | BMJ Open
![Quality-adjusted life year distributions for Enhanced Care (grey lines)... | Download Scientific Diagram Quality-adjusted life year distributions for Enhanced Care (grey lines)... | Download Scientific Diagram](https://www.researchgate.net/publication/352162767/figure/fig2/AS:1031566226620416@1622955962059/Quality-adjusted-life-year-distributions-for-Enhanced-Care-grey-lines-and-Collaborative.png)
Quality-adjusted life year distributions for Enhanced Care (grey lines)... | Download Scientific Diagram
![Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening - Value in Health Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening - Value in Health](https://www.valueinhealthjournal.com/cms/asset/041a3bf5-bbdb-4e80-b3a7-28e45487f8bf/gr1.jpg)
Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening - Value in Health
![US pricing watchdog finds Novartis, Biogen rare disease treatments too pricey | S&P Global Market Intelligence US pricing watchdog finds Novartis, Biogen rare disease treatments too pricey | S&P Global Market Intelligence](https://www.snl.com/articles/397201762.png)
US pricing watchdog finds Novartis, Biogen rare disease treatments too pricey | S&P Global Market Intelligence
![Rebecca Plevin on Twitter: "For math-averse reporters, @kristingourlay offers formula for calculating drug cost-effectiveness @ReportingHealth http://t.co/Vn0BpIueXd" / Twitter Rebecca Plevin on Twitter: "For math-averse reporters, @kristingourlay offers formula for calculating drug cost-effectiveness @ReportingHealth http://t.co/Vn0BpIueXd" / Twitter](https://pbs.twimg.com/media/CN_vzV2UsAACOIz.png:large)
Rebecca Plevin on Twitter: "For math-averse reporters, @kristingourlay offers formula for calculating drug cost-effectiveness @ReportingHealth http://t.co/Vn0BpIueXd" / Twitter
![Quality-adjusted life year (QALY) gains for 5 extra years of life using... | Download Scientific Diagram Quality-adjusted life year (QALY) gains for 5 extra years of life using... | Download Scientific Diagram](https://www.researchgate.net/publication/267738898/figure/fig2/AS:601712805036039@1520470920390/Quality-adjusted-life-year-QALY-gains-for-5-extra-years-of-life-using-the-age-specific.png)